The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale, and use of cefodizime, an antibiotic drug produced by South Korea-based Daewoong Bio Inc. This decision was made in response to the company’s written refusal to undergo an overseas production site dynamic inspection by the NMPA, which is considered a violation of China’s Drug Administration Law and the Regulations on the Administration of Overseas Inspection of Drugs and Medical Devices.
Cefodizime, a semi-synthetic third-generation cephalosporin, is known for its antibacterial activity against both Gram-positive and Gram-negative bacteria. It is primarily used in clinical settings to treat infections and inflammatory diseases caused by sensitive bacteria such as Streptococcus and pneumococcus.- Flcube.com
